1961-77-9

Basic information

• Product Name: CHLORMADINON
• Synonyms: 20-dione,6-chloro-17-hydroxy-pregna-6-diene-3;6-chloro-17-hydroxypregna-4,6-diene-3,20-dione;CHLORMADINON;6-chloro-17-alpha-hydroxypregna-4,6-diene-3,20-dione;PREGNA-4,6-DIENE-3,20-DIONE,6-CHLORO-17-HYDROXY-;6-Chloro-6-dehydro-17- hydroxyprogesterone;6-Chloro-6-dehydro-17-α-hydroxyprogesterone;Chlormadinone Solution, 100ppm
• CAS NO: 1961-77-9
• Molecular Formula: C₂₁H₂₇ClO₃
• Molecular Weight: 362.89
• EINECS: 217-802-3
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Steroids
• Mol File: 1961-77-9.mol
• Article Data: 5

Chemical Properties

• Melting Point: 213°C
• Boiling Point: 478.95°C (rough estimate)
• Flash Point: 260.2 °C
• Appearance: /
• Density: 1.0559 (rough estimate)
• Vapor Pressure: 2.18E-12mmHg at 25°C
• Refractive Index: 1.4585 (estimate)
• PKA: 12.87±0.70(Predicted)
• CAS DataBase Reference: CHLORMADINON(CAS DataBase Reference)
• NIST Chemistry Reference: CHLORMADINON(1961-77-9)
• EPA Substance Registry System: CHLORMADINON(1961-77-9)

Safety Data

• Hazardous Substances Data: 1961-77-9(Hazardous Substances Data)

Usage

Description

CHLORMADINON is a synthetic steroidal compound, classified as a progestin. It is an off-white to pale yellow solid and has been utilized in the pharmaceutical industry for its hormonal properties.

Uses

Used in Pharmaceutical Industry:
CHLORMADINON is used as an ingredient in oral contraceptives for its ability to inhibit ovulation, alter the cervical mucus, and affect the endometrium, thereby preventing pregnancy. It is typically combined with other hormones, such as estrogens, to enhance its effectiveness and reduce potential side effects.

InChI:InChI=1/C21H27ClO3/c1-12(23)21(25)9-6-16-14-11-18(22)17-10-13(24)4-7-19(17,2)15(14)5-8-20(16,21)3/h10-11,14-16,25H,4-9H2,1-3H3/t14-,15+,16+,19-,20+,21+/m1/s1

Upstream product

• 302-22-7 chlormadinone acetate 
• 68-96-2 17-hydroxyprogesterone 
• 2477-60-3 17α-hydroxypregna-4,6-diene-3,20-dione 

Downstream Products

• 302-22-7 chlormadinone acetate 

Relevant articles and documents

Preparation method of chlormadinone acetate

A preparation method of chlormadinone acetate includes: using 17a hydroxyl progestin as a raw material, dissolving the same in an organic solvent, reacting with bromine under acid catalysis to obtaina bromination product, and enabling the bromination product to react with lithium bromide and lithium carbonate in the organic solvent for debromination to obtain 6 dehydrogenation product in the organic solvent; dissolving the 6 dehydrogenation product in the organic solvent to react with organic peroxy acid to obtain epoxide; dissolving the epoxide in the organic solvent to be in additive reaction with hydrogen chloride gas, and dehydrating in a strong acid solution to obtain chlormadinone; dissolving chlormadinone in the organic solvent to react with acetic anhydride under acid catalysis toobtain chlormadinone acetate. HPLC content is 99.0-99.5%, and total yield of four-step synthetic reaction is 80-82%. Compared with conventional synthetic methods, the preparation method is simple andconvenient to operate, economical, environment-friendly and high in synthetic total yield and in product quality, and cost is lowered by 40-45%; the solvent used in the method can be recycled, so that industrial production is facilitated greatly.

Development of a new sensitive and specific time-resolved fluoroimmunoassay (TR-FIA) of chlormadinone acetate in the serum of treated menopausal women.

We describe the development of a serum chlormadinone acetate (CMA) time-resolved fluoroimmunoassay (TR-FIA). We prepared haptens (3-CMO-chlormadinone acetate and 6-chloropregna-4,6-dien-17,20-diol-3-one-20-hemisuccinate), biotinylated tracers (3(biotinylaminopropylamido) 3-CMO-chlormadinone acetate and 3-(6-chloropregna-4,6-dien-17,20-diol-3-one-20-hemisuccinylamino)1-biotinylaminopropane), and immunogens necessary for eliciting two antibodies (anti-chlormadinone acetate 3-CMO/BSA and anti-chlormadinone 20-hemisuccinate/BSA). The specificity of the assay was rigorously studied to eliminate possible interference by polar metabolites of CMA, particularly 17 alpha-acetoxy-6-chloro-3beta-hydroxypregna-4,6-diene-20-one (3beta-hydroxy metabolite), employing an easy-to-use ethylene glycol chromatographic step prior to immunoassay, so as to separate the polar metabolites, in particular the 3beta-hydroxy-CMA metabolite, from the intact CMA. The choice of the anti-CMA antibody was guided by the high assay sensitivity obtained with the anti-CMA 3-CMO/BSA antibody. The detection limit was 51pg/ml. Interassay reproducibility CVs were between 2.6 and 4.5%. This TR-FIA thus appeared to be a sensitive, specific, precise, and consequently well-suited method for measurement of serum CMA during a pharmacokinetic study in women.

Novel 17-esters of 17α-hydroxy gestogens, compositions containing such compounds, processes for their preparation and methods of treatment therewith

This invention relates to novel 17α-esters of gestogens having an antitumour activity and to the preparation thereof. The invention is also concerned with pharmaceutical compositions containing the said compounds, and method of treatment therewith.